Furthermore, treatment with a PPARα agonist improved steatosis in fatty liver Shionogi mice and reduced hepatic triglyceride level by inducing expression of several genes involved in the turnover of fatty acids, e.g., ACADL[36]. Here, ACADL is linked to steatosis.